R Kevin Stafford

Title: R Kevin Stafford: Innovator in Metabolic Pathway Engineering

Introduction

R Kevin Stafford is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of metabolic engineering, particularly in the production of ascorbic acid. His innovative work has implications for biotechnology and pharmaceuticals.

Latest Patents

R Kevin Stafford holds 1 patent for his invention titled "Metabolic pathway engineering to increase production of ascorbic acid." This patent focuses on recombinant microorganisms that have been genetically modified to convert 2,5-diketo-D-gluconic acid (2,5-DKG) into 2-keto-L-gulonic acid (2-KLG). The research determined the secondary metabolites and metabolic pathways that lead to the diversion of these compounds, blocking the conversion of 2-KLG to L-iodonic acid (IA) or 2,5-DKG to 5-keto-D-gluconate (5-KDH).

Career Highlights

R Kevin Stafford is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to further explore the applications of his research in real-world scenarios.

Collaborations

Throughout his career, R Kevin Stafford has collaborated with esteemed colleagues such as Stephen P Anderson and Robert A Lazarus. These collaborations have enriched his research and contributed to advancements in metabolic engineering.

Conclusion

R Kevin Stafford's contributions to metabolic pathway engineering exemplify the innovative spirit of modern biotechnology. His work not only enhances our understanding of metabolic processes but also paves the way for future advancements in the production of essential compounds like ascorbic acid.